PressJuly 6, 2026 AtaiBeckley doses last patient in Phase 2b Elumina trial of VLS-01 for treatment-resistant depression
PressJune 24, 2026 Helus Pharma reports APPROACH Phase 3 enrollment past 86% and launches $50M offering
PressJune 22, 2026 Definium's Phase 3 Emerge study of DT120 (LSD) meets primary endpoint in major depression
PressJune 10, 2026 Optimi Health completes first psilocybin export to the United Kingdom for a Phase 2 trial
PressJune 8, 2026 Optimi Health secures naturally derived ibogaine to expand its psychedelic drug portfolio
PressMay 29, 2026 Optimi Health welcomes expanded Australian Authorized Prescriber framework for psilocybin and MDMA
